慢病毒基因治疗联合减低强度预处理治疗镰状细胞病:1/2期试验
这项首次人体1/2期研究纳入7例镰状细胞病患者,采用慢病毒载体(GbGM)修饰的自体造血干细胞联合减低强度预处理移植,随访2-7年。主要可行性终点均达到,中位4次采集(范围4-8)达到目标细胞剂量,全部产品达到目标载体拷贝数;7例均出现持续HbFG16D表达及严重血管闭塞事件减少>80%(次要终点)。
要点
- 7例患者中位4次采集(范围4-8)达到目标CD34+细胞剂量,全部产品达到目标载体拷贝数。
- 研究期间7例共发生503例不良事件,最常见为2-3级血管闭塞危象。
- 4级血小板减少中位持续5天,4级中性粒细胞减少中位持续8天。
核心结论
- 减低强度预处理联合GbGM慢病毒载体自体造血干细胞移植在7例镰状细胞病患者中达到主要可行性与安全性终点,7例均出现持续HbFG16D表达及严重血管闭塞事件减少>80%(次要终点)。
- 作者认为需要更大规模试验评估减低强度预处理的获益。
研究设计与样本
- 首次人体1/2期研究,纳入7例镰状细胞病患者,采用减低强度预处理联合慢病毒载体(GbGM)修饰的自体造血干细胞移植,随访2-7年。
- GbGM编码表达强效抗镰状化胎儿血红蛋白HbFG16D的修饰γ-珠蛋白基因。
- 主要研究目标为安全性(不良事件发生及中性粒细胞减少和血小板减少持续时间)与治疗可行性;临床试验注册号NCT02186418。
主要发现
- 主要可行性终点达到:每公斤体重至少采集8×10^6 CD34+细胞、至少4×10^6 CD34+细胞每公斤体重成功转导、输注后1年平均载体拷贝数>0.01拷贝/细胞的受试者数。
- 达到目标细胞剂量所需采集中位数为4次(范围4-8),全部产品达到目标载体拷贝数。
- 研究期间7例患者共发生503例不良事件,最常见为2-3级血管闭塞危象。
- 4级血小板减少中位持续5天,4级中性粒细胞减少中位持续8天。
- 全部7例患者出现持续HbFG16D表达及严重血管闭塞事件减少>80%(次要终点)。
关键数值与推荐
- 可行性终点:每公斤体重至少采集8×10^6 CD34+细胞、至少4×10^6 CD34+细胞每公斤体重成功转导、输注后1年平均载体拷贝数>0.01拷贝/细胞的受试者数均达到。
- 安全性:7例患者共503例不良事件,最常见为2-3级血管闭塞危象;4级血小板减少中位持续5天,4级中性粒细胞减少中位持续8天。
- 次要终点:全部7例患者严重血管闭塞事件减少>80%,并出现持续HbFG16D表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 临床试验在输注第7例患者后终止,因预定主要终点已达到且行业资助完成。
- 作者认为需要更大规模试验评估减低强度预处理的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous transplantation of gene-modified cells for treatment of sickle cell disease has involved myeloablative conditioning with associated cytopenias and toxicities. We report results of seven patients treated in a first-in-human phase 1/2 study for sickle cell disease using reduced-intensity conditioning transplant of autologous hematopoietic stem cells genetically modified with a lentiviral vector (GbGM), with 2-7 yr of follow-up. GbGM encodes a modified γ-globin gene that expresses a potent anti-sickling fetal hemoglobin, HbFG16D. The primary study objectives were safety (occurrence of adverse events and duration of neutropenia and thrombocytopenia) and feasibility of treatment. Primary feasibility endpoints of collection of at least 8 × 106 CD34+ cells per kg body weight, successful transduction of a minimum of 4 × 106 CD34+ cells per kg body weight and the number of subjects with an average vector copy number of >0.01 copies per cell 1 yr after infusion were met. A median of 4 collections (range, 4-8) were needed to achieve the target cell dose, and all products achieved the target vector copy number. There were 503 adverse events in the seven patients throughout the study period, the most common being grade 2-3 vaso-occlusive crisis. Median duration of grade 4 thrombocytopenia was 5 d and of grade 4 neutropenia was 8 d. All seven patients exhibited sustained HbFG16D expression and >80% reduction in severe vaso-occlusive events (secondary endpoints). The clinical trial was terminated after infusion of the seventh patient as the predetermined primary endpoints were met and industry funding was complete. Larger trials are warranted to evaluate the benefits of reduced-intensity conditioning. ClinicalTrials.gov registration number: NCT02186418 .
引用
- Grimley M, Davies SM, Shrestha A, et al. Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Nat Med. 2025. PMID: 40419809. doi:10.1038/s41591-025-03662-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。